Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Posts Flat Q4 Revenue and R&D Spend as Profit Tumbles 31 Percent

NEW YORK (GenomeWeb News) — Molecular Devices today said fourth-quarter revenues remained virtually flat as R&D spending was unchanged and profit decreased 31 percent.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $52.8 million from $52.7 million year over year.
 
Molecular Devices did not break out revenues by business unit.
 
R&D spending was flat at $6.3 million in both quarters.
 
The company said profit declined to $4 million from $5.8 million in the year-ago period.
 
Molecular Devices said it had around $22.8 million in cash and equivalents as of Dec. 31.
 
Last week MDS said it plans to acquire Molecular Devices for $615 million in cash.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.